by Anna Lukacs MSc, PhD | 09 Dec 2016
Methods from PMI's systems toxicology are not limited to harm reduction on tobacco; transparency in research allows for true collaboration across industry players and academia.
Similarly to other areas of biology, the science behind testing potentially adverse effects of novel consumer products – toxicology – is rapidly evolving thus creating an intensive discussion each year at the meeting of the American College of Toxicology. This is where researchers from the pharmaceutical, biotechnological and tobacco industries meet and share breakthroughs and challenges across all branches of toxicology.
The conference provided an excellent platform for active conversations between regulators and PMI as displayed during the Q&A session that followed Nikolai Ivanov’s presentation of milestones on the development and assessment of reduced-risk products. In total, PMI’s R&D facility was represented by seven researchers. They jointly showcased the three pillars of a truly comprehensive toxicological program directed at novel consumer products: in vitro studies, in vivo assessment and clinical evaluation.
As the tobacco industry uses methods from across toxicology, other arms of toxicology may employ practices from the tobacco industry. Therefore the scientific approach that PMI applies for the assessment of Reduced-Risk Products is not limited to the study of nicotine delivery systems. This two-way interaction would not be possible without complete scientific openness. Collaboration and transparency were the key themes underlying the SciPi event of the conference where PMI researchers could get real-time expert feedback on their ten posters, a new initiative driving this exemplary dialogue.